In June 2008, therefore, a protocol amendment was implemented to widen the eligibility criteria to more pragmatically include patients assessed by their clinician to be at high risk of early breast cancer relapse irrespective of hormone receptor status. This evidence concerns the gene NR4A1 and breast cancer.